Altimmune to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th, 2023GlobeNewsWire • 06/16/23
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data in Treatment of NAFLD at Upcoming EASL International Liver Congress™ 2023GlobeNewsWire • 06/15/23
Altimmune Announces First Quarter 2023 Financial Results and Provides a Business UpdateGlobeNewsWire • 05/11/23
Altimmune to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023GlobeNewsWire • 05/04/23
Altimmune Completes Enrollment in Phase 2 Clinical Trial of HepTcell™, an Immunotherapeutic for Chronic Hepatitis BGlobeNewsWire • 04/11/23
Altimmune Appoints Former GSK Executive Catherine Angell Sohn, Pharm.D. to its Board of DirectorsGlobeNewsWire • 03/27/23
Wall Street Absolutely Loved This Biotech Stock. But It Just Crashed More Than 50%.The Motley Fool • 03/22/23
Altimmune Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business UpdateGlobeNewsWire • 02/28/23
Altimmune to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023GlobeNewsWire • 02/21/23
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 7, 2023GlobeNewsWire • 01/04/23